OmniSeq News
OmniSeq Offers Differentiating Platform to Clinically Detect Rare Genetic Alterations to Identify Patients Eligible for New, Targeted Therapy for Lung and Thyroid Cancer
NGS Test Uses RNA-Sequencing to Detect RET Fusions and DNA-Sequencing to Detect RET Mutations BUFFALO, N.Y., June 29, 2020 /PRNewswire/ -- OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the benefits of its OmniSeq Advance®...
OmniSeq Appoints Chief Medical Officer, Roger D. Klein, M.D., J.D., FCAP
FOR IMMEDIATE RELEASE MEDIA CONTACT: Sawyer Lipari Lambert & Co. 313.309.9551 slipari@lambert.com OmniSeq Appoints Chief Medical Officer, Roger D. Klein, M.D., J.D., FCAP Leading molecular diagnostic company’s new hire to support oncology product development...
Roswell Park’s Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort
Roswell Park’s Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort
OmniSeq Names Dr. Shengle Zhang as New Lab Director
FOR IMMEDIATE RELEASE MEDIA CONTACT: Sawyer Lipari Lambert & Co. 313.309.9551 slipari@lambert.com OmniSeq Names Dr. Shengle Zhang as New Lab Director Fast-growing cancer diagnostic laboratory continues focus on development of innovative product breakthroughs...
Schoenborn named CEO at OmniSeq
June 26, 2019 Buffalo News - OmniSeq Inc., a molecular diagnostic laboratory on the Buffalo Niagara Medical Campus, has a new CEO. Margot P. Schoenborn, formerly the company's chief administrative officer, has been promoted to the position.
People in the News
June 26, 2019 GenomeWeb - OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO.
Margot Schoenborn becomes CEO of fast-growing OmniSeq
Business First - Margot Schoenborn has quite the resume. Now she gets to add yet another interesting professional experience: biotech boss. Schoenborn has been named the CEO of OmniSeq, which develops and sells molecular diagnostic tests that show cancer patients what...
OmniSeq Board Names Margot Schoenborn to Succeed Mark Gardner as CEO
June 26, 2019 BUFFALO, N.Y., June 26, 2019 (GLOBE NEWSWIRE) -- OmniSeq, Inc. named Margot P. Schoenborn to succeed Mark Gardner as the chief executive officer of the molecular diagnostics and precision medicine company.
OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment Agreement
BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today an extension of their...
Follow Us on Twitter
November is #LungCancerAwarenessMonth. NCCN® recommends biomarker testing in #lungcancer be performed via a broad, panel-based approach, and to further consider RNA-based NGS to maximize detection of fusion events.@LabCorp @OmniSeq
https://www.linkedin.com/posts/labcorp_lungcancerawarenessmonth-lungcancer-activity-6737002499707809792-yGUk
A new laboratory and diagnostic industry coalition has been formed to advocate for insurance coverage for comprehensive genomic profiling. @labcorp @integratedoncology @illumina https://www.targetedonc.com/view/7-leading-diagnostic-companies-unite-to-form-access-to-comprehensive-genomic-profiling-coalition
#oncology #precisionmedicine
Get AMPed! Tomorrow from 1-2PM EST visit OmniSeq's Poster: ST20, Abstract: 917082, Category: Solid Tumors, Title: "Cancer-testis antigen detection by targeted RNA sequencing."
#associationformolecularpathology
#PrecisionMedicine
#pathology
#oncology
Visit: https://amp20.amp.org/
WATCH NOW! Learn how OmniSeq's Comprehensive Genomic Profiling (CGP) is becoming standard of care in oncology. @illumina https://www.illumina.com/destination/flexible-capabilities-cgp.html?SCID=2020-271ECL4546
#Cancer #PrecisionMedicine #oncology #pathology #hope
Predictive Power of OmniSeq! #SITC2020 Thurs, Nov. 12(4:50-5:20 pm EST) and Sat, Nov. 14(1-1:30 pm EST) Poster#66:Complex markers of survival from pembrolizumab: the potential predictive role of tumor mutational burden (TMB) and KRAS.
https://jitc.bmj.com/content/8/Suppl_3/A71
#lungcancer #oncology